Dynamics Special Purpose Corp. (DYNS): Price and Financial Metrics
DYNS Price/Volume Stats
| Current price | $7.51 | 52-week high | $10.54 |
| Prev. close | $8.00 | 52-week low | $7.18 |
| Day low | $7.18 | Volume | 92,100 |
| Day high | $8.44 | Avg. volume | 65,747 |
| 50-day MA | $9.76 | Dividend yield | N/A |
| 200-day MA | $9.88 | Market Cap | 178.10M |
DYNS Stock Price Chart Interactive Chart >
Dynamics Special Purpose Corp. (DYNS) Company Bio
Dynamics Special Purpose Corp. focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or other business combination with one or more businesses. The company was incorporated in 2021 and is based in Redwood City, California.
Latest DYNS News From Around the Web
Below are the latest news stories about DYNAMICS SPECIAL PURPOSE CORP that investors may wish to consider to help them evaluate DYNS as an investment opportunity.
Could The Dynamics Special Purpose Corp. (NASDAQ:DYNS) Ownership Structure Tell Us Something Useful?A look at the shareholders of Dynamics Special Purpose Corp. ( NASDAQ:DYNS ) can tell us which group is most powerful... |
Senti Bio to Present at the 40th Annual J.P. Morgan Virtual Healthcare ConferenceSOUTH SAN FRANCISCO, Calif., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (“Senti Bio”), a leading Gene Circuit company today announced that Tim Lu, MD, PhD, Chief Executive Officer and Co-Founder, will present a corporate overview at the 40th Annual J.P. Morgan Virtual Healthcare Conference on Tuesday, January 11, 2022 at 2:00 p.m. EST. Senti Bio uses its Gene Circuit platform to program cell and gene therapies with potentially enhanced capabilities. Gene Circuits, which are create |
Peninsula 'gene circuits' company taking blank-check route to go publicInitially targeting cancers, Senti believes cells and genes can be engineered to be triggered like computer circuits to perform specific, unique tasks. |
Senti Bio and Dynamics Special Purpose Corp. Announce Business Combination Agreement to Create Publicly Listed Company Pioneering Gene Circuit-Engineered Cell and Gene Therapies- Business combination with Dynamics Special Purpose Corp. (Nasdaq: DYNS) is expected to provide more than $296 million in gross proceeds, over $153 million of which is fully committed in a common stock Private Investment in Public Equity (“PIPE”) financing and from non-redemption agreements - - Over $86 million in non-redemption agreements committed from existing Dynamics investors including funds managed by ARK Investment Management LLC, funds and accounts managed by Counterpoint Global (Morga |
Former Illumina execs, Grail co-founder raise $21M for biotech startupIllumina Inc.'s ex-chief technology officer and former colleagues raised $21 million for a startup biotech company that, according to a job posting, is seeking engineers and scientists "with a passion to develop the next generation of technologies for unraveling complexities of biology beyond what is within the realm of possibility today. |
DYNS Price Returns
| 1-mo | N/A |
| 3-mo | N/A |
| 6-mo | N/A |
| 1-year | N/A |
| 3-year | N/A |
| 5-year | N/A |
| YTD | N/A |
| 2022 | 0.00% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...